D., Ph. D. Present Position

Peer-reviewed research articles (*corresponding author)

1. 
   Buonavista, N., Balzano, C., Pontarotti, P., Le Paslier, D. and Goldstein, P. 1992. Molecular linkage of human CTLA-4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics. Jul; 13(3):856-861.
   
2. 
   Balzano, C., Buonavista, N., Rouvier, E. and Goldstein, P. 1992. CTLA-4 CD28, similar protein, neighboring genes. International Journal of Cancer. Suppl 7, 28-32.
   
3. 
   Cornillon, S., Foa, C., Davoust, J., Buonavista, N., Gross, J. D. and Goldstein, P. 1994. Programmed cell death in Dictyostelium. Journal of Cell Science. Oct; 107(10): 2691-2704.
   
4. 
   Couissiner-Paris, P., Bourgeois, A., Dessein, H., Bacellar, O., Rodriguez, V. Jr., Kohlstadt, S., Buonavista, N., Pene, J. and Dessein, A. J. 1995. Identification of a major T cell immunogen in the anti-schistosome response of adult residents in an area endemic of Schistosoma mansoni. European Journal of Immunology. 24 (4): 903-910.
   
5. 
   Scholler, N., Fu, N., Yang, Y., Ye, Z. M., Goodman, G. E., Hellström, K. E. and Hellström, I. 1999. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 96(20):11531-11536.
   
6. 
   Hellström, I., Ledbetter, J. A., Scholler, N., Yang, Y., Ye, Z. M., Goodman, G. E., Pullman, J., Hayden-Ledbetter, M. and Hellström, K. E. 2001. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proceedings of the National Academy of Sciences of the United States of America. Jun 5; 98(12): 6783-6788.
   
7. 
   *Scholler, N., Hayden-Ledbetter, M., Hellström, I., Hellström, K. E. and Ledbetter, J. A. 2001. CD83 is a Sialic Acid-Binding Immunoglobin-Like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of Activated CD8⁺ T Cells. Journal of Immunology. 166: 3865-3872.
   
8. 
   *Scholler, N., Hayden-Ledbetter, M., Dahlin, A., Hellström, I., Hellström, K. E. and Ledbetter, J. A. 2002. CD83 Regulates the Development of Cellular Immunity. Journal of Immunology. 168: 2599-2602.
   
9. 
   Disis, M. L.+, Scholler, N.+, Dahlin, A., Pullman, J., Knutson, K. L., Hellström, K. E. and Hellström, I. 2003. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Molecular Cancer Therapy. Oct; 2(10):995-1002.(+these authors equally contributed to the work).
   
10. 
    McIntosh, M. W., Drescher, C., Karlan, B., Scholler, N., Urban, N., Hellström, I. and Hellström, K. E. 2004. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecologic Oncology. 95(1):9-15.
    
11. 
    *Scholler, N., Crawford, M., Sato, A., Drescher, C. W., O’Briant, K. C., Kiviat, N., Anderson, G. L. and Urban, N. Bead-based ELISA assays for validation of ovarian cancer early detection markers. Clinical Cancer Research. 2006. 12: 2117-2124.
    
12. 
    *Scholler, N., Garvik, B., Quarles, T., Jiang, S. and Urban, N. 2006. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. Journal of Immunological Methods. Dec 20; 317(1-2):132-143. Epub 2006 Oct 30.
    
13. 
    *Scholler, N., Garvik, B., Hayden-Ledbetter, M., Kline, T. and Urban, N. 2007. Development of a CA125-Mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Letters. Mar 8; 247(1):130-136. Epub 2006 May 4.
    
14. 
    Bergan, L., Gross, J. A., Nevin, B., Urban, N., and *Scholler, N. 2007. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Letters. Oct 8; 255(2):263-74. Epub 2007 Jun 7.
    
15. 
    Loch, C. M., Ramirez, A. B., Liu, Y., Sather, C. L., Delrow, J.J., Garvik, B., Scholler, N., Urban, N., McIntosh, M. W. and Lampe, P. D. Use of High Density Antibody Arrays to Validate and Discover Cancer Serum Biomarkers. Molecular Oncology. Volume 1, Issue 3, December 2007, Pages 313-320
    
16. 
    *Scholler, N., Lowe, K. A., Bergan, L. A., Kampani, A. V., Ng, V., Forrest, R. M., Thorpe, J. D., Gross, J. A., Garvik, B. M., Drapkin, R., Anderson, G. L. and Urban, N. Use of yeast-secreted in vivo biotinylated recombinant antibodies (biobodies) in bead–based ELISA. Clinical Cancer Research. 2008 May 1:14(9):2647-55
    
17. 
    Faca, V., Song, K., Wang, H., Zhang, Q., Krasnoselsky, A., Ireton, R., Newcomb, L., Plentz, R., Glukhova, V., Phanstiel, D., Gurumurthy, S., Redston, M. S., Brenner, D., Anderson, M., Misek, D., Scholler, N., Urban, N., Barnett, M., Edelstein, C., Goodman, G., Thornquist, M., McIntosh, M., DePinho, R. A., Bardeesy, N. and Hanash S. Markers for human pancreatic cancer based on plasma proteome analysis of a mouse model. PLoS Med. 2008 Jun 10;5(6):e123.
    
18. 
    Palmer C., Duan X., Hawley S., Scholler N., Thorpe J., Sahota R., Wong M., Wray A., Drescher C., McIntosh M., Brown P., Nelson B., Urban N. Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian Cancer. PLoS ONE - 2008 Jul 9;3(7):e2633.
    
19. 
    Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008 Jun 25. Jun 25;113(3):484-489. DOI: 10.1002/cncr.23577
    
20. 
    *Scholler N., Gross JA., Garvik B., Wells L., Liu Y., Loch CM., Ramirez AB., McIntosh MW., Lampe PD., Urban N. Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. Journal of Translational Medicine. 2008, 6:41
    
21. 
    Lowe K., Shah C., Wallace E., Anderson G., Paley P., McIntosh M., Andersen R., Scholler N., Bergan L., Thorpe J., Urban N., Drescher C. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Post-menopausal Women at High-Risk for Ovarian Cancer. Cancer Epidemiology, Biomarkers & Prevention. 2008 Sep;17(9):2480-7.
    
22. 
    C. Shah, K. Lowe, P. Paley, E. Wallace, G. Anderson, M. McIntosh, R. Andersen, N. Scholler, L. Bergan, J. Thorpe, N. Urban, C. Drescher. “Influence of ovarian cancer Risk status on the Diagnostic Performance of the serum Biomarkers Mesothelin. HE4 and CA125”.-Cancer Epidemiology Biomarkers & Prevention (CEBC) Prev. 2009 May;18(5):1365-72
    
23. 
    Gonzalez, J.M., Ofori E., Burd I., Chai J., Scholler N., Elovitz M.A.: “Maternal mortality from systemic illness: unraveling the contribution of the immune response”. Am J Obstet Gynecol 2009, 200, 430 e1-8.
    
24. 
    Chen, A., Kozak, D., Battersby, B.J., Forrest, R.M., Scholler, N., Urban, N., and Trau, M. “Antifouling Surface Layers for Improved Signal-to-Noise of Particle-Based Immunoassays” –Langmuir. 2009, 25 (23), pp 13510–13515
    
25. 
    Anderson G.L., McIntosh M.,Wu L., Thorpe J.D., Bergan L., Goodman G., Barnett M., Thornquist M.D., Scholler N., Kim N., O’Briant K., Drescher C., Urban N.. “Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study” –JNCI. 2010 Vol. 102, Issue 1, January 6.
    
26. 
    Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P and Urban N. “Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.” -Gynecol Oncol. 2010 Mar;116(3):378-83. Epub 2009 Nov 28.
    
27. 
    Aizhi Zhao, Selene Nunez-Cruz, Chunsheng Li, George Coukos, Don L. Siegel and *Nathalie Scholler. “Rapid isolation of high affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast display/secretory scFv library platform.” JIM, Jan 5; 363(2):221-32. Epub 2010 Sep 15.
    
28. 
    Selene Nunez-Cruz, Denise C. Connolly and Nathalie Scholler. “An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.” JoVE , 2010 Nov 28. (45), pii:2146, doi:10.3791/2146. [Epub ahead of print]
    
29. 
    Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011 Mar;4(3):375-83.
    
30. 
    Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011 Mar;4(3):365-74.
    
31. 
    Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther. 2011 Aug 1;12(3). [Epub ahead of print] PubMed PMID: 21617380
    
32. 
    Nicole Urban, Jason D. Thorpe, Martin McIntosh, Lindsay Bergan, Robin Forrest, Archana Kampani, Nathalie Scholler, Kathy O’Briant, Charles Drescher, Dan Cramer, Chris Berg. ^"Potential role of HE4 in multimodal screening for epithelial ovarian cancer" JNCI brief communication 2011; 103:1-5 [Epub ahead of print.]
    
33. 
    Eleftheria Kalogera; Nathalie Scholler; Cecelia Powless; Amy Weaver; Ronny Drapkin; Jinping Li; Shi-Wen Jiang; Karl Podratz; Nicole Urban; Sean Christopher Dowdy. “Correlation of Serum HE4 with Tumor Size and Myometrial Invasion in Endometrial Cancer”. Gynecologic Oncology [online October 28, 2011]
    
34. 
    Evripidis Lanitis, Mathilde Poussin, Ian Hagemann, Raphael Sandaltzopoulos, Nathalie Scholler, and Daniel J. Powell, Jr. “Redirected anti-tumor activity of primary human lymphocytes transduced with a fully-human anti-mesothelin chimeric receptor”. Molecular Therapy [Online Nov 29, 2011]  
    
35. 
    Denarda Dangaj, Karen Abbott, Ananda Mookerjee, Aizhi Zhao, Pamela S. Kirby, Raphael Sandaltzopoulos, Daniel J. Powell Jr., Antonin Lamazière, Don L. Siegel, Claude Wolf, and *Nathalie Scholler. “Mannose receptor engagement by mesothelin GPI anchor polarizes tumor associated macrophages and is blocked by a recombinant antibody directed against mannose receptor domain 4.” PLos One [Online Dec 6, 2011]
    
36. 
    Katarzyna Urbanska, Evripidis Lanitis, Mathilde Poussin, Rachel Lynn, Brian P Gavin, Sander Kelderman, Jason Yu, Nathalie Scholler and Daniel J Powell Jr. “A novel immune receptor expressed by T cells for universal targeting of diverse and multiple tumor associated antigens”. Cancer Research. 012 Apr 1;72(7):1844-52. Epub 2012 Feb 7.
    

Submitted peer-reviewed research articles.

Yonghai Li, Donald L Siegel, Nathalie Scholler and David E Kaplan. “Glypican-3-specific scFv isolation and validation for use in hepatocellular carcinoma” accepted pending minor revisions.

Reviews

*Scholler, N. and Urban N. CA125 in Ovarian Cancer. Biomarkers in Medicine 1(4), December 2007, Pages 513-523.

*Scholler, N., Mesothelin, Encyclopedia of Cancer, 2^nd edition, 1836-1940 (2008)

*Scholler, N.,2^nd Oncology Biomarkers Conference (Miami, FL), Thomson Reuters Scientific division (2009)

*Scholler, N.6^th Cancer Drugs R&D Conference (Philadelphia, PA), , Thomson Reuters Scientific division (2009)

*Scholler N., “Oncology Biomarkers. the Investigational Drugs journal 2009 12(4): © Thomson Reuters (Scientific) Ltd ISSN 2040-3410

Sasaroli D., Coukos G. and *Scholler N. “Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?” - Biomarkers in Medicine. Prev. 2009 May;18(5):1365-72

Tanyi J.L and *Scholler N. “From the endometrium physiology to a comprehensive strategy for the discovery of ovarian cancer biomarkers.” Oncology reviews. 2010 March, Vol. 4, Number 1, pages 43-50.

*Scholler, N, 3^rd Oncology Biomarkers Conference (San Diego, CA), Thomson Reuters Scientific division. (2011)

Tanyi, J.L. and *Scholler, N. “Oncology Biomarkers for Detection and Therapeutic Monitoring of Gynecologic Malignancies”. Front Biosci (Elite Ed). 2012 Jan 1;4:1097-110.
Book Chapters

Mantia-Smaldone, G.M. and *Scholler, N. "Ovarian Cancer" chapter of InTech book project, Open Access publisher. ISBN: 978-953-307-812-0. (in press)

*Scholler, N. "Selection of antibody fragments by yeast display" chapter of “Antibody Engineering: methods and protocols" section in the lab-protocol based 'Methods in Molecular Biology' series, Humana Press editors. (in press)

Nunez-Cruz, S. and *Scholler, N. "Immunocompetent mouse model of ovarian cancer for in vivo imaging" chapter of “Ovarian Cancer”, Humana Press editors (in press)

Editorial

*Scholler, N. Novel targeting strategies using recombinant antibodies for early diagnosis and therapy of ovarian cancer. Future Medicine Therapy. 2010, 7(3), 209-212
Patents

1.